Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus

PHASE3CompletedINTERVENTIONAL
Enrollment

629

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

January 31, 2011

Study Completion Date

July 31, 2012

Conditions
Hepatitis B, Chronic
Interventions
DRUG

Entecavir

Tablets, Oral, 1mg, once daily, 100 weeks

DRUG

Tenofovir

Tablets, Oral, 300 mg, once daily

DRUG

Adefovir

Tablets, Oral, 10mg, once daily, 100 weeks

DRUG

Lamivudine

Tablets, Oral, 100mg, once daily, 100 weeks

Trial Locations (67)

100

Local Institution, Taipei

333

Local Institution, Taoyuan District

1502

Local Institution, Manila

2031

Local Institution, Randwick

2139

Local Institution, Concord

6000

Local Institution, Cebu City

10350

Local Institution, Jakarta

10700

Local Institution, Bangkok

11527

Local Institution, Athens

35100

Local Institution, Bornova Izmir

50012

Local Institution, Antella, Firenze

50200

Local Institution, Chiang Mai

50603

Local Institution, Kuala Lumpur

70403

Local Institution, Tainan R.o.c.

80756

Local Institution, Kaohsiung City

88586

Local Institution, Kota Kinabalu

90035

Local Institution, Porto Alegre Rs

105275

Local Institution, Moscow

110002

Local Institution, New Delhi

115446

Local Institution, Moscow

119074

Local Institution, Singapore

141001

Local Institution, Ludhiana

160012

Local Institution, Chandigarh

190103

Local Institution, Saint Petersburg

191167

Local Institution, Saint Petersburg

226014

Local Institution, Lucknow

380006

Local Institution, Ahmedabad

420767

Local Institution, Bucheon-si

452014

Local Institution, Indore

610808

Local Institution, Trabzon

626770

Local Institution, Yangsan

632004

Local Institution, Vellore

06030

University Of Connecticut Health Center, Farmington

T2N 4N1

Local Institution, Calgary

Unknown

Local Institution, Hong Kong

Local Institution, Shatin

Local Institution, Tai Po

41-500

Local Institution, Chorzów

25-317

Local Institution, Kielce

91-347

Local Institution, Lodz

20-081

Local Institution, Lublin

01-201

Local Institution, Warsaw

130-702

Local Institution, Seoul

682-714

Local Institution, Ulsan

425-707

Local Institution, Ansan-si

431-070

Local Institution, Anyang-si

463 712

Local Institution, Seongnam-si

442-723

Local Institution, Suwon

411-706

Local Institution, Koyang

400-711

Local Institution, Incheon

139-872

Local Institution, Seoul

200-704

Local Institution, Chuncheon

700-721

Local Institution, Daegu

210-711

Local Institution, Gangneung

405-760

Local Institution, Incheon

602-739

Local Institution, Pusan

110-744

Local Institution, Seoul

120-752

Local Institution, Seoul

135-710

Local Institution, Seoul

135-720

Local Institution, Seoul

136-705

Local Institution, Seoul

137-040

Local Institution, Seoul

138-736

Local Institution, Seoul

143-729

Local Institution, Seoul

152-703

Local Institution, Seoul

156-755

Local Institution, Seoul

443-721

Local Institution, Suwon

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY